The efficacy and safety of taletrectinib in patients with TKI-naïve or crizotinib-pretreated ROS1-positive non–small cell lung cancer (NSCLC).Wěi Li, Caicun Zhou, Huiwen Ma et al.|Journal of Clinical Oncology|2022Cited by 12